Medlab Middle East to Return as Standalone Event in 2023
By LabMedica International staff writers Posted on 11 Jan 2022 |
Informa Markets (London, UK), organizers of Medlab Middle East, have announced that the MENA region’s leading exhibition for the laboratory industry will return to a standalone event in 2023.
This announcement follows unprecedented demand from exhibitors and visitors for the 2022 edition of the show, which takes place at the Dubai World Trade Centre from 24-27 January 2022. As a result of the pandemic, Medlab Middle East and Arab Health co-located in 2021 to provide a platform for both the laboratory and general healthcare industries to come together, reconnect and do business face-to-face in a safe and secure environment. However, following high-level demand from leading laboratory companies to showcase their offering in a dedicated space, and from attendees keen to capitalize on the latest laboratory releases, the event will now revert to a standalone format, with dates confirmed for 7-9 February 2023.
The 2022 edition of Medlab Middle East is expected to welcome more than 400 exhibitors, a 100% increase from 2021. Key players participating in this edition include Roche, Siemens, Beckman Coulter, Abbott, Biomerieux and Mindray. In addition to the growth in exhibitors, which is expected to increase to over 500 in 2023, country pavilions have risen from nine in 2021 to 10 in 2022, with that figure expected to increase to 14 in 2023.
Fueling the surge in exhibitors is the anticipated growth in the global laboratory industry. According to the Global Clinical Laboratory Market – Analysis by test, end-user, by region, by country (2021 edition), the global laboratory market is expected to grow by a Compound Annual Growth Rate (CAGR) of 6% between 2021 and 2026, which puts the predicted value of the global laboratory market at US$ 33.07 billion by 2026. The report attributed the growth rate to the increasing number of lifestyle-related ailments and chronic illnesses, and spurts of infectious diseases in different parts of the world. The introduction of accurate and technologically advanced products, such as companion diagnostics, biochips, and microarrays, has bolstered the demand for early disease detection. Moreover, rapid technological advancements to enhance productivity and reduce costs are anticipated to boost the market further. These solutions offer clinicians maximum efficiency and minimum risk of errors, which has driven the uptake of services in the market.
“Advances in the medical laboratory have been pivotal in the defense against the continued threat that COVID-19 poses to industries around the world,” said Tom Coleman, Exhibition Director of Medlab Middle East. “Due to the speed at which the laboratory industry has responded to these threats by developing solutions, products and technology to counter the impact of the pandemic, we have seen a surge in companies wanting to showcase their latest innovations and from buyers eager to capitalize on these advances.”
“As a result of this demand, following the 2022 edition of the show, which will be held from 24 -27 January, Medlab Middle East will return as a standalone event in 2023 with a total of six halls, showcasing the latest innovations and new technologies being utilized in the laboratory industry,” added Coleman.
Related Links:
Informa Markets
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus